Elaine Benaksas
Corporate Officer/Principal chez American Chemical Society
Profil
Elaine Benaksas is currently a member of the American Chemical Society.
Prior to this, she worked as an Assistant Research Professor at Loma Linda University and as Vice President-Research & Development at Encore Pharmaceuticals, Inc. Dr. Benaksas received her undergraduate and doctorate degrees from the University of California, Los Angeles.
Postes actifs de Elaine Benaksas
| Sociétés | Poste | Début |
|---|---|---|
American Chemical Society
 American Chemical Society Miscellaneous Commercial ServicesCommercial Services American Chemical Society engages as a scientific society which supports scientific inquiry in the field of chemistry. The company was founded in 1876 and is headquartered in Washington, DC. | Corporate Officer/Principal | - |
Anciens postes connus de Elaine Benaksas
| Sociétés | Poste | Fin |
|---|---|---|
Encore Pharmaceuticals, Inc.
 Encore Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encore Pharmaceuticals, Inc. (EPI) is a drug discovery and development company with advanced proprietary products for the treatment and prevention of cancer and neurologic and cardiovascular diseases. EPI's principal drug innovations have come from discoveries made by researchers at Loma Linda University Medical Center (LLUMC). EPI was founded in 1997 and concluded a technology transfer license agreement with LLUMC in January 1999. The discovery operation continues to be located in the LLUMC environment where operations in 1999 were expanded to include clinical development of EPI's lead drug candidate E-7869 (now known as MPC-7869) for treatment of prostate and colon cancer. The company's research efforts have also led to the discovery of a -tocopherol (member of the Vitamin E family) metabolite designated as E-8110 (also known as LLU- ) and bioanalogs which have natriuretic (sodium excretion) activity. These compounds are being examined for their anti-hypertensive, anti-oxidant and anti-cancer properties. Patent applications for EPI drug discoveries have been filed and are in review worldwide | Directeur Technique/Scientifique/R&D | - |
| Loma Linda University | Corporate Officer/Principal | - |
Formation de Elaine Benaksas
| University of California, Los Angeles | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
American Chemical Society
American Chemical Society Miscellaneous Commercial ServicesCommercial Services American Chemical Society engages as a scientific society which supports scientific inquiry in the field of chemistry. The company was founded in 1876 and is headquartered in Washington, DC. | Commercial Services |
Encore Pharmaceuticals, Inc.
Encore Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encore Pharmaceuticals, Inc. (EPI) is a drug discovery and development company with advanced proprietary products for the treatment and prevention of cancer and neurologic and cardiovascular diseases. EPI's principal drug innovations have come from discoveries made by researchers at Loma Linda University Medical Center (LLUMC). EPI was founded in 1997 and concluded a technology transfer license agreement with LLUMC in January 1999. The discovery operation continues to be located in the LLUMC environment where operations in 1999 were expanded to include clinical development of EPI's lead drug candidate E-7869 (now known as MPC-7869) for treatment of prostate and colon cancer. The company's research efforts have also led to the discovery of a -tocopherol (member of the Vitamin E family) metabolite designated as E-8110 (also known as LLU- ) and bioanalogs which have natriuretic (sodium excretion) activity. These compounds are being examined for their anti-hypertensive, anti-oxidant and anti-cancer properties. Patent applications for EPI drug discoveries have been filed and are in review worldwide | Health Technology |